Related references
Note: Only part of the references are listed.Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival
Miriam Lenhard et al.
HISTOPATHOLOGY (2011)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni et al.
LANCET ONCOLOGY (2011)
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis - Results of a randomized controlled trial
Sylvie Negrier et al.
CANCER (2007)
Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
J Hasan et al.
BRITISH JOURNAL OF CANCER (2005)
Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma
CH Lee et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2005)
The β2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor
S Maudsley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
